References
Ahlers-Dannen KE, Spicer MM, Fisher RA (2020). RGS Proteins as Critical Regulators of Motor Function and Their Implications in Parkinson’s Disease. Mol Pharmacol98 (6): 730-738.
Arcuri L, Novello S, Frassineti M, Mercatelli D, Pisano CA, Morella I, et al. (2018). Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists. Br J Pharmacol 175 (5): 782-796.
Bastide MF, Meissner WG, Picconi B, Fasano S, Fernagut PO, Feyder M, et al. (2015). Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson’s disease. Prog Neurobiol .
Berman DM, Wilkie TM, Gilman AG (1996). GAIP and RGS4 are GTPase-activating proteins for the Gi subfamily of G protein alpha subunits. Cell86 (3): 445-452.
Blazer LL, Storaska AJ, Jutkiewicz EM, Turner EM, Calcagno M, Wade SM, et al. (2015). Selectivity and anti-Parkinson’s potential of thiadiazolidinone RGS4 inhibitors.ACS chemical neuroscience 6 (6): 911-919.
Brugnoli A, Pisano CA, Morari M (2020). Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats. Neurobiol Dis144: 105044.
Buzas B, Rosenberger J, Cox BM (1998). Activity and cyclic AMP-dependent regulation of nociceptin/orphanin FQ gene expression in primary neuronal and astrocyte cultures. J Neurochem 71 (2): 556-563.
Cenci MA, Crossman AR (2018). Animal models of l-dopa-induced dyskinesia in Parkinson’s disease. Mov Disord 33 (6): 889-899.
Cenci MA, Lee CS, Bjorklund A (1998). L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA.Eur J Neurosci 10 (8): 2694-2706.
Cenci MA, Lundblad M (2007). Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson’s disease in rats and mice. Curr Protoc NeurosciChapter 9: Unit 9 25.
Cifelli C, Rose RA, Zhang H, Voigtlaender-Bolz J, Bolz SS, Backx PH, et al. (2008). RGS4 regulates parasympathetic signaling and heart rate control in the sinoatrial node. Circ Res 103 (5): 527-535.
Curtis MJ, Alexander S, Cirino G, Docherty JR, George CH, Giembycz MA, et al. (2018). Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers. Br J Pharmacol175 (7): 987-993.
Dripps IJ, Wang Q, Neubig RR, Rice KC, Traynor JR, Jutkiewicz EM (2017). The role of regulator of G protein signaling 4 in delta-opioid receptor-mediated behaviors.Psychopharmacology (Berl) 234 (1): 29-39.
Duty S, Jenner P (2011). Animal models of Parkinson’s disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol164 (4): 1357-1391.
Ebert PJ, Campbell DB, Levitt P (2006). Bacterial artificial chromosome transgenic analysis of dynamic expression patterns of regulator of G-protein signaling 4 during development. II. Subcortical regions. Neuroscience142 (4): 1163-1181.
Feng H, Sjogren B, Karaj B, Shaw V, Gezer A, Neubig RR (2017). Movement disorder in GNAO1 encephalopathy associated with gain-of-function mutations. Neurology89 (8): 762-770.
Ferrari F, Malfacini D, Journigan BV, Bird MF, Trapella C, Guerrini R, et al. (2017). In vitro pharmacological characterization of a novel unbiased NOP receptor-selective nonpeptide agonist AT-403. Pharmacology research & perspectives 5 (4).
Garzon J, Rodriguez-Diaz M, Lopez-Fando A, Sanchez-Blazquez P (2001). RGS9 proteins facilitate acute tolerance to mu-opioid effects. Eur J Neurosci13 (4): 801-811.
Geurts M, Maloteaux JM, Hermans E (2003). Altered expression of regulators of G-protein signaling (RGS) mRNAs in the striatum of rats undergoing dopamine depletion.Biochem Pharmacol 66 (7): 1163-1170.
Gold SJ, Ni YG, Dohlman HG, Nestler EJ (1997). Regulators of G-protein signaling (RGS) proteins: region-specific expression of nine subtypes in rat brain. J Neurosci 17 (20): 8024-8037.
Gross JD, Kaski SW, Schmidt KT, Cogan ES, Boyt KM, Wix K, et al. (2019). Role of RGS12 in the differential regulation of kappa opioid receptor-dependent signaling and behavior. Neuropsychopharmacology 44 (10):1728-1741.
Han MH, Renthal W, Ring RH, Rahman Z, Psifogeorgou K, Howland D, et al. (2010). Brain region specific actions of regulator of G protein signaling 4 oppose morphine reward and dependence but promote analgesia. Biol Psychiatry67 (8): 761-769.
Jutkiewicz EM, Rice KC, Traynor JR, Woods JH (2005). Separation of the convulsions and antidepressant-like effects produced by the delta-opioid agonist SNC80 in rats.Psychopharmacology (Berl) 182 (4): 588-596.
Kimple AJ, Bosch DE, Giguere PM, Siderovski DP (2011). Regulators of G-protein signaling and their Galpha substrates: promises and challenges in their use as drug discovery targets. Pharmacol Rev 63 (3): 728-749.
Ko WK, Martin-Negrier ML, Bezard E, Crossman AR, Ravenscroft P (2014). RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson’s disease. Neurobiol Dis 70: 138-148.
Lerner TN, Kreitzer AC (2012). RGS4 is required for dopaminergic control of striatal LTD and susceptibility to parkinsonian motor deficits. Neuron 73 (2):347-359.
Marti M, Mela F, Fantin M, Zucchini S, Brown JM, Witta J, et al. (2005). Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson’s disease. J Neurosci25 (42): 9591-9601.
Marti M, Mela F, Guerrini R, Calo G, Bianchi C, Morari M (2004). Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release. J Neurochem91 (6): 1501-1504.
Marti M, Rodi D, Li Q, Guerrini R, Fasano S, Morella I, et al. (2012). Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias. J Neurosci 32 (46): 16106-16119.
Mercatelli D, Bezard E, Eleopra R, Zaveri NT, Morari M (2020). Managing Parkinson’s disease: moving ON with NOP. Br J Pharmacol 177 (1): 28-47.
Neal CR, Jr., Mansour A, Reinscheid R, Nothacker HP, Civelli O, Akil H, et al. (1999). Opioid receptor-like (ORL1) receptor distribution in the rat central nervous system: comparison of ORL1 receptor mRNA expression with (125)I-[(14)Tyr]-orphanin FQ binding. J Comp Neurol412 (4): 563-605.
Olianas MC, Dedoni S, Boi M, Onali P (2008). Activation of nociceptin/orphanin FQ-NOP receptor system inhibits tyrosine hydroxylase phosphorylation, dopamine synthesis, and dopamine D(1) receptor signaling in rat nucleus accumbens and dorsal striatum. J Neurochem 107 (2): 544-556.
Paolone G, Brugnoli A, Arcuri L, Mercatelli D, Morari M (2015). Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.Mov Disord 30 (13): 1728-1738.
Papale A, Morella IM, Indrigo MT, Bernardi RE, Marrone L, Marchisella F, et al. (2016). Impairment of cocaine-mediated behaviours in mice by clinically relevant Ras-ERK inhibitors. eLife 5 .
Pavon N, Martin AB, Mendialdua A, Moratalla R (2006). ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.Biol Psychiatry 59 (1): 64-74.
Paxinos G, Watson C (1986). The rat brain in stereotaxic coordinates . 2nd edn. Academic Press: Sydney ; Orlando.
Pisanò CA, Brugnoli A, Novello S, Caccia C, Keywood C, Melloni E, et al. (2020). Safinamide inhibits in vivo glutamate release in a rat model of Parkinson’s disease. Neuropharmacology 167 .
Psifogeorgou K, Papakosta P, Russo SJ, Neve RL, Kardassis D, Gold SJ, et al. (2007). RGS9-2 is a negative modulator of mu-opioid receptor function. J Neurochem103 (2): 617-625.
Runne H, Regulier E, Kuhn A, Zala D, Gokce O, Perrin V, et al. (2008). Dysregulation of gene expression in primary neuron models of Huntington’s disease shows that polyglutamine-related effects on the striatal transcriptome may not be dependent on brain circuitry. J Neurosci28 (39): 9723-9731.
Sakloth F, Polizu C, Bertherat F, Zachariou V (2020). Regulators of G protein signaling in analgesia and addiction. Mol Pharmacol .
Santini E, Valjent E, Usiello A, Carta M, Borgkvist A, Girault JA, et al. (2007). Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci27 (26): 6995-7005.
Schmidt ER, Morello F, Pasterkamp RJ (2012). Dissection and culture of mouse dopaminergic and striatal explants in three-dimensional collagen matrix assays. Journal of visualized experiments : JoVE (61).
Schwarting RK, Huston JP (1996). The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol 50 (2-3): 275-331.
Senese NB, Kandasamy R, Kochan KE, Traynor JR (2020). Regulator of G-Protein Signaling (RGS) Protein Modulation of Opioid Receptor Signaling as a Potential Target for Pain Management. Frontiers in molecular neuroscience 13: 5.
Shen W, Plotkin JL, Francardo V, Ko WK, Xie Z, Li Q, et al. (2015). M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia. Neuron 88 (4): 762-773.
Sjogren B (2017). The evolution of regulators of G protein signalling proteins as drug targets - 20 years in the making: IUPHAR Review 21. Br J Pharmacol174 (6): 427-437.
Stratinaki M, Varidaki A, Mitsi V, Ghose S, Magida J, Dias C, et al. (2013). Regulator of G protein signaling 4 [corrected] is a crucial modulator of antidepressant drug action in depression and neuropathic pain models. Proc Natl Acad Sci U S A 110 (20): 8254-8259.
Tesmer JJ, Berman DM, Gilman AG, Sprang SR (1997). Structure of RGS4 bound to AlF4–activated G(i alpha1): stabilization of the transition state for GTP hydrolysis.Cell 89 (2): 251-261.
Toll L, Bruchas MR, Calo G, Cox BM, Zaveri NT (2016). Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.Pharmacol Rev 68 (2): 419-457.
Traynor J (2012). mu-Opioid receptors and regulators of G protein signaling (RGS) proteins: from a symposium on new concepts in mu-opioid pharmacology. Drug Alcohol Depend121 (3): 173-180.
Traynor JR, Neubig RR (2005). Regulators of G protein signaling & drugs of abuse. Mol Interv5 (1): 30-41.
Turner EM, Blazer LL, Neubig RR, Husbands SM (2012). Small Molecule Inhibitors of Regulator of G Protein Signalling (RGS) Proteins. ACS medicinal chemistry letters3 (2): 146-150.
Viaro R, Sanchez-Pernaute R, Marti M, Trapella C, Isacson O, Morari M (2008). Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism. Neurobiol Dis30 (3): 430-438.
Xie GX, Yanagisawa Y, Ito E, Maruyama K, Han X, Kim KJ, et al. (2005). N-terminally truncated variant of the mouse GAIP/RGS19 lacks selectivity of full-length GAIP/RGS19 protein in regulating ORL1 receptor signaling. J Mol Biol353 (5): 1081-1092.
Zachariou V, Georgescu D, Sanchez N, Rahman Z, DiLeone R, Berton O, et al. (2003). Essential role for RGS9 in opiate action. Proc Natl Acad Sci U S A100 (23): 13656-13661.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8